A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results

R.E O'Cearbhaill,K Homicsko,A Wolfer,P.A Disilvestro,D.M O'Malley,P Sabbatini,A Orcurto,D Barras,L Shohara,T Ricciardi,M Macri,A Ryan,R.R Venhaus,B.J Monk,G Coukos

doi:10.1016/j.ygyno.2020.06.086

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results

R.E O'Cearbhaill, K Homicsko + Show 13 more

https://doi.org/10.1016/j.ygyno.2020.06.086

Copy DOI

Journal: Gynecologic Oncology	Publication Date: Oct 1, 2020
Citations: 5

Affiliation: Memorial Sloan Kettering Cancer Center, University of Lausanne, Brown University, James Cancer Hospital, Ludwig Cancer Research, Arizona Oncology, University Hospital of Lausanne

#Pegylated Liposomal Doxorubicin #Platinum-resistant Recurrent Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objective: The objectives of this study, where durvalumab (durva, an anti-PD-L1 antibody) is added to pegylated liposomal doxorubin (PLD), standard therapy for platinum-resistant ovarian cancer (PROC), are to evaluate the efficacy and safety of the combination and to identify genomic characteristics associated with response and progression-free survival (PFS).

Full Text